PsyBio is committed to innovate, develop, and optimize technology related to its ever growing psycho-targeted portfolio through formal regulatory pathways Based on feedback received, PsyBio intends to request its initial compound-specific pre-IND meeting OXFORD, Ohio and COCONUT CREEK, Fla., Dec. 7, 2021 /CNW/ – PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) (“PsyBio” or the “Company“)…


Previous articlePTSF88 – Dr. Ben Sessa of Awakn Life Sciences + Josh Bartch of Mydecine Innovations Group
Next articlePsychedelic Bulletin: Our Dispatch from Horizons NYC; NIDA to Study Delix Compounds